CVS Health Corporation $CVS Shares Sold by Blume Capital Management Inc.

Blume Capital Management Inc. lessened its holdings in CVS Health Corporation (NYSE:CVS) by 13.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 44,074 shares of the pharmacy operator’s stock after selling 6,645 shares during the quarter. Blume Capital Management Inc.’s holdings in CVS Health were worth $3,498,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd boosted its holdings in CVS Health by 407.2% in the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after acquiring an additional 281 shares in the last quarter. Ares Financial Consulting LLC acquired a new stake in CVS Health in the fourth quarter worth about $29,000. Dogwood Wealth Management LLC lifted its holdings in shares of CVS Health by 93.7% during the fourth quarter. Dogwood Wealth Management LLC now owns 370 shares of the pharmacy operator’s stock worth $29,000 after purchasing an additional 179 shares during the period. GoalVest Advisory LLC acquired a new stake in shares of CVS Health during the fourth quarter worth about $32,000. Finally, Financial Consulate Inc. lifted its holdings in shares of CVS Health by 99.6% during the fourth quarter. Financial Consulate Inc. now owns 499 shares of the pharmacy operator’s stock worth $40,000 after purchasing an additional 249 shares during the period. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Trading Up 0.1%

Shares of NYSE:CVS opened at $95.95 on Monday. CVS Health Corporation has a 12-month low of $58.50 and a 12-month high of $98.43. The company has a market capitalization of $122.42 billion, a PE ratio of 42.27, a PEG ratio of 0.94 and a beta of 0.60. The business has a 50 day moving average of $78.71 and a two-hundred day moving average of $78.57. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The company had revenue of $100.43 billion during the quarter, compared to the consensus estimate of $94.99 billion. During the same period in the previous year, the company posted $2.25 earnings per share. CVS Health’s revenue for the quarter was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, analysts forecast that CVS Health Corporation will post 7.44 EPS for the current year.

CVS Health Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd were issued a $0.665 dividend. The ex-dividend date of this dividend was Thursday, April 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 2.8%. CVS Health’s payout ratio is presently 117.18%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on CVS shares. Leerink Partners reaffirmed an “outperform” rating and set a $98.00 target price on shares of CVS Health in a report on Thursday, March 5th. The Goldman Sachs Group lifted their target price on CVS Health from $95.00 to $97.00 and gave the stock a “buy” rating in a report on Thursday, February 12th. Wolfe Research decreased their target price on CVS Health from $100.00 to $97.00 and set an “outperform” rating for the company in a report on Monday, March 2nd. DA Davidson lifted their target price on CVS Health from $80.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Finally, JPMorgan Chase & Co. lifted their target price on CVS Health from $101.00 to $111.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. Twenty-two research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $98.08.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Morgan Stanley raised its price target on CVS Health and kept an overweight rating, signaling confidence in further upside after the company’s stronger-than-expected quarterly results. Morgan Stanley Issues Positive Forecast for CVS Health (NYSE:CVS) Stock Price
• Positive Sentiment: Argus also lifted its outlook for CVS Health, adding to the wave of analyst support that may be helping shares move higher. Argus Issues Positive Forecast for CVS Health (NYSE:CVS) Stock Price
• Positive Sentiment: CVS reported solid Q1 2026 earnings recently, beating estimates on both revenue and adjusted EPS, which continues to drive investor optimism about execution and valuation. Here is Why CVS Health (CVS) is One of the Cheap Stocks to Buy For the Next 10 Years
• Positive Sentiment: CVS and WGU launched an online pre-pharmacy degree program to help build a stronger pharmacist pipeline, a move that could support long-term staffing and service growth. CVS Health® and WGU launch online pre-pharmacy degree program for future pharmacists nationwide
• Neutral Sentiment: CVS advanced its portfolio reset by selling Omnicare after bankruptcy court approval, which simplifies the business and removes an underperforming unit, but also confirms ongoing restructuring. CVS Refocuses On Core Health Platform With Omnicare Sale And Drone Rollout
• Neutral Sentiment: CVS also highlighted community and brand-building initiatives in Rhode Island, including its economic impact report and expanded WIC acceptance, which are positive for reputation but less likely to move the stock on their own. CVS Health’s Annual Impact in Rhode Island

Insider Buying and Selling at CVS Health

In other news, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the transaction, the executive vice president directly owned 10,133 shares of the company’s stock, valued at $907,714.14. This represents a 87.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 0.85% of the stock is currently owned by insiders.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.